Injection pens for the load loss therapy Wegovy, manufactured by Novo Nordisk A/S, on show throughout a information convention in Mumbai, India, June 24, 2025.
Dhiraj Singh | Bloomberg | Getty Photographs
Tens of millions of older People in Medicare are about to achieve entry to weight problems medicine for the primary time — however that landmark shift could also be flying underneath the radar for a lot of of them.
Beginning Wednesday, eligible beneficiaries can get weight problems medicine by way of Medicare’s new Bridge demonstration program for a month-to-month copay of simply $50. The protection marks a long-sought victory for sufferers, physicians and weight problems advocates who’ve pushed for broader entry to the blockbuster remedies from Novo Nordisk and Eli Lilly, which have remained out of attain for a lot of People.
However a staggering 82% of all older People — together with 79% of Republicans and 84% of Democrats — say they’re unaware that Medicare is about to start masking weight problems medicine, in accordance with a survey launched in early June by the Weight problems Care Advocacy Community. The survey, performed in late March amongst greater than 2,100 adults ages 65 and older, was accomplished weeks earlier than the federal government introduced it would lengthen the Bridge program by way of 2027.
That knowledge could not come as a shock: Whereas the federal government has performed sturdy outreach to healthcare suppliers and pharmacists, some physicians and different consultants advised CNBC that they’ve observed restricted promoting of the brand new protection to most of the people from the Facilities for Medicare & Medicaid Companies or Novo and Lilly.
There could also be good causes for it. CMS has performed restricted public outreach on this system forward of July 1 as a result of beneficiaries are “most moved to take motion” when a profit is definitely out there to them, an company official advised reporters on Thursday. They added that CMS will put out extra promotions after the launch, “within the curiosity of being good stewards of our taxpayer {dollars}.”
Different consultants additionally advised CNBC that it could come down to creating certain suppliers and pharmacies are ready and sources are in place earlier than pursuing broad public outreach.
Nonetheless, some consultants say the lack of expertise could delay some eligible adults from making the most of the brand new protection and getting on the remedies instantly.
“I’ve not seen a number of data on the market for the general public, and I feel there are going to be loads of individuals who have zero data of the Bridge program,” mentioned Dr. Shauna Levy, medical director of the Tulane Bariatric and Weight Loss Middle. “And I feel for sufferers, it is simply going to take even longer for them to search out out about it, after which see in the event that they’re eligible.”
In contrast to conventional Medicare drug protection, enrollment within the Bridge program shouldn’t be automated. Sufferers should meet eligibility necessities, receive a prescription and obtain prior authorization approval by way of CMS earlier than protection begins.
A quiet lead-up to launch
The comparatively quiet lead-up to the rollout stands in distinction to the advertising campaigns Novo and Lilly have traditionally deployed for his or her weight problems and diabetes medicines, which have appeared in all places from tv commercials to subway ads.
Novo spent practically $500 million on U.S. promoting for its weight problems drug Wegovy and its diabetes counterpart Ozempic within the first 9 months of 2025, greater than double the simply over $200 million Lilly spent selling its rival injections, Zepbound and Mounjaro, Reuters reported, citing knowledge from the ad-tracking agency MediaRadar.
“I used to be slightly shocked that there hasn’t been extra promoting by Lilly and Novo for seniors to be able to get their prescription,” mentioned Leerink Companions analyst David Risinger, including that it takes time to e book an appointment with a supplier to acquire one.
The Eli Lilly and Novo Nordisk logos.
Mike Blake | Tom Little | Reuters
Medicare beneficiaries have to be enrolled in Half D, a prescription drug plan, to qualify for the brand new protection. However as a result of the Bridge program is run instantly by CMS slightly than by way of Half D plans, personal insurers need not play a task in educating beneficiaries in regards to the new protection.
“All of that advertising benefit of getting it run by way of the Half D plans does not exist,” mentioned Kenneth Thorpe, well being coverage professor at Emory College.
He mentioned “getting the phrase out” about this system and who’s eligible will probably be among the many largest challenges of the rollout.
The eligibility for this system is broad, however sure sufferers is not going to qualify. That features these already receiving protection of a GLP-1 from their Half D plan for a use already lined by Medicare, akin to Kind 2 diabetes, heart problems threat discount or sleep apnea.
Whereas promoting of the GLP-1 protection could not mirror earlier rollouts, there was some promotion forward of the launch.
Focused mentions on social media and Novo’s web site are promoting the Bridge program, mentioned Jamey Millar, the corporate’s govt vp of U.S. operations, in an interview on Wednesday.
He acknowledged that no linear TV adverts are selling the brand new protection, however mentioned he believes consciousness amongst sufferers will come from suppliers and pharmacies. CMS has performed complete outreach to each in regards to the upcoming program, in accordance with some physicians.
Millar likened the dynamic to the annual flu vaccine or shingles shot for older adults.
“Any seniors that stroll right into a retail pharmacy post-July 1, on common, they’re on eight medicines, most of them oral, so the pharmacist has a possibility to say, do you know about Bridge?” he advised CNBC. “In order that they’re outfitted to do it, after which [health-care providers] as properly.”
The transfer could also be intentional
Adamkaz | E+ | Getty Photographs
The restricted public outreach forward of July 1 could also be by design. A slower rollout might give physicians, pharmacies and CMS time to arrange earlier than a doubtlessly giant variety of beneficiaries start searching for therapy.
“We usually take the view that allow’s be sure that the physicians are ready, just like what we did with Foundayo, earlier than getting broad consciousness for shoppers,” Ilya Yuffa, president of Lilly USA and world buyer capabilities, mentioned in an interview on Wednesday.
Yuffa was referring to the latest launch of Lilly’s weight problems tablet, Foundayo. Constructing consciousness amongst suppliers and the broader healthcare system first helps keep away from “friction” between sufferers and physicians, he mentioned.
Nonetheless, Yuffa mentioned shoppers ought to anticipate to see broader advertising efforts from Lilly across the availability of Foundayo and one type of Zepbound by way of the Bridge program.
Some consultants prompt CMS may additionally be attempting to make sure this system can deal with an inflow of curiosity. Beneficiaries should receive prior authorization earlier than receiving protection, and processing these requests might turn out to be a major endeavor if demand surges instantly after launch.
“It could be, let’s get the primary month down and see what errors we make, so we will repair it, slightly than all the pieces crashes and burns inside a month or two,” mentioned Dr. Holly Lofton, director of the Medical Weight Administration Program at NYU Langone.
“The factor is, the entry is there, and hopefully the world will get round,” she mentioned.
